Chimerix to Host Annual Investor Update on April 27, 2017

DURHAM, N.C., April 20, 2017 -- Chimerix, Inc. (Nasdaq:CMRX), a biopharmaceutical company committed to discovering, developing and commercializing medicines that address significant, unmet medical needs, today announced that it will host the Company's annual investor update event on April 27, 2017, from 4:30 p.m. to 6:30 p.m. ET. 

Garrett Nichols, MD, MS, Chimerix's Chief Medical Officer will provide details and timelines on the Company's planned AdAPT trial (Study 999) of short-course oral brincidofovir for the treatment of adenovirus infection. In addition, Dr. Nichols will review newly available results from the single ascending dose study of IV brincidofovir, and plans to generate multiple-dose PK and safety data in healthy subjects as well as patient populations. These data are intended to inform the planned pivotal MVP-peds study for Multi-Viral Prevention of DNA viral infections. 

The event will also feature keynote presentations from Thomas Lion, MD, PhD, Professor and Medical Director of the Children's Cancer Research Institute (Vienna, Austria) who will address the rapidly changing field of adenovirus infections in immunocompromised patients. Joshua Hill, MD, Associate in the Vaccine and Infectious Disease Division at the Fred Hutchinson Cancer Research Center (Seattle, Washington) will share his research on the frequency of multiple viral infections in both adult and pediatric transplant recipients and the impact of viral infections on survival in the first year post-transplant. Linda Richardson, Chimerix's Chief Commercial Officer, will provide an overview of the potential market for brincidofovir oral and IV formulations in Europe and the US. 

To access the live webcast, please visit the Investor Relations section of Chimerix's website at http://ir.chimerix.com/events.cfm. An archived replay of the webcast will also be available at the same location. 

About Chimerix
Chimerix is a biopharmaceutical company dedicated to discovering and developing medicines that improve outcomes for immunocompromised patients. Chimerix's proprietary lipid conjugate technology has produced brincidofovir (BCV, CMX001); CMX157, which was licensed to ContraVir Pharmaceuticals; and earlier-stage compounds. Chimerix recently announced a new clinical candidate, CMX521, for the treatment and/or prevention of norovirus. For further information, please visit Chimerix's website, www.chimerix.com. 

Forward-Looking Statements
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks, uncertainties and other factors, including the possibility that there may not be a viable continued development path for BCV, that any clinical trials we may conduct will not demonstrate adequate efficacy and safety of BCV, that enrollment in clinical trials we may conduct may be insufficient or slower than we anticipate, that the FDA and other regulatory authorities may not approve BCV or BCV-based regimens, and that marketing approvals, if granted, may have significant limitations on their use. As a result, BCV may never be successfully commercialized. In addition, Chimerix may be unable to file for regulatory approval for BCV with other regulatory authorities. These risks, uncertainties and other factors could cause actual results to differ materially from those expressed or implied by such forward-looking statements. Risks are described more fully in the Company's filings with the Securities and Exchange Commission, including without limitation the Company's most recent Annual Report on Form 10-K and other documents subsequently filed with or furnished to the Securities and Exchange Commission. All forward-looking statements contained in this Current Report on Form 8-K speak only as of the date on which they were made. The Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

CONTACT:
Investor Relations: 

[email protected]
or
Will O'Connor
Stern Investor Relations
[email protected]
212-362-1200
 
Media:

Becky Vonsiatsky
W2O Group
[email protected]
413-478-2003